Drug Trial Radar · NCT05720767
HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study
Last checked: Nov 19, 2026Latest source record: Mar 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
28
Actual
Start
Nov 4, 2022
Primary completion
Feb 5, 2023
Study completion Feb 5, 2023
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Feb 9, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1, Open-label, 2-Part, 2-Period Fixed-Sequence Crossover Study to Assess the Effect of Itraconazole, a CYP3A and P-glycoprotein Inhibitor, and the Effect of Rifampin, a CYP Enzyme Inducer, on the Pharmacokinetics of HMPL-523 in Healthy Volunteers
Conditions
- Relapsed or Refractory Lymphoma
Interventions
HMPL-523Drug
HMPL-523 is a selective small-molecule SYK inhibitor.
ItraconazoleDrug
Itraconazole is an FDA approved synthetic triazole antifungal agent
RifampinDrug
Rifampin is an FDA approved semisynthetic antiobiotic derivative indicated in the treatment of both tuberculosis and meningococcal carrier state
Primary outcomes
What the sponsor says the trial is designed to measure.
- PK parameter for HMPL-523: AUC0-tTime frame: Day 1 to 18
- PK parameter for HMPL-523: AUC0-infTime frame: Day 1 to 18
- PK parameter for HMPL-523: CmaxTime frame: Day 1 to 18
Locations
1 site in 1 country. Site status is shown where the registry gives one.
PPD Austin
Austin, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.